Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
2.000
+0.100 (5.26%)
At close: Aug 6, 2026, 4:00 PM EDT
2.030
+0.030 (1.50%)
Pre-market: Aug 7, 2026, 7:39 AM EDT
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $26.22M in the quarter ending March 31, 2026, with 191.89% growth. This brings the company's revenue in the last twelve months to $92.62M, up 940.05% year-over-year. In the year 2025, Autolus Therapeutics had annual revenue of $75.39M with 652.77% growth.
Revenue (ttm)
$92.62M
Revenue Growth
+940.05%
P/S Ratio
5.75
Revenue / Employee
$122,844
Employees
754
Market Cap
532.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.39M | 65.37M | 652.77% |
| Dec 31, 2024 | 10.01M | 8.32M | 489.80% |
| Dec 31, 2023 | 1.70M | -4.68M | -73.38% |
| Dec 31, 2022 | 6.38M | 4.87M | 323.23% |
| Dec 31, 2021 | 1.51M | 1.27M | 522.73% |
| Dec 31, 2020 | 242.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Sep 30, 2018 | - | - | - |
| Sep 30, 2017 | - | - | - |
| Sep 30, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 98.99M |
| Assembly Biosciences | 71.10M |
| Verastem | 49.59M |
| Scribe Therapeutics | 36.28M |
| Adlai Nortye | 5.00M |
| Prime Medicine | 4.07M |
| ProKidney | 889.00K |
| Silence Therapeutics | 839.00K |
AUTL News
- 3 days ago - Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026 - GlobeNewsWire
- 3 days ago - Autolus Therapeutics reports preliminary Q2 revenue $45M, consensus $29.86M - TheFly
- 4 days ago - Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 6 weeks ago - Autolus Therapeutics to Participate in Upcoming Investor Conference - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Receives Prix Galien UK Award - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts